To assess gynecologic oncology and radiation oncology clinician attitudes, prescribing patterns, and barriers to hormonal therapy after chemoradiotherapy for cervical cancer, highlighting its significance in survivorship care.
Key Findings:
89.0% of participants completed the survey, with a majority being attending physicians.
99.3% of GYO clinicians would prescribe HT after chemoradiotherapy compared to 73.8% of RO clinicians.
Barriers to prescribing HT included capacity for long-term management (21.3% GYO, 42.5% RO) and lack of society guidelines (12.5% GYO, 12.5% RO).
Interpretation:
Most clinicians are willing to prescribe HT for LACC patients post-chemoradiotherapy, but barriers hinder implementation, indicating a significant gap between knowledge and practice that needs to be addressed.
Limitations:
Self-selection bias and recall bias may affect the reliability of the findings.
Sampling bias and low response rate limit the generalizability of the results.
The small sample size of RO clinicians may not represent the broader population.
Conclusion:
Despite the willingness to prescribe HT, awareness of guidelines and comfort in prescribing need improvement to enhance survivorship care for cervical cancer patients, addressing identified barriers is crucial.
More than 80% of women who were partially up to date reported a wellness visit in the prior year, suggesting missed opportunities for screening engagement in primary care.
